26/04/2021 à 15:03

Inaccurate wordings have been corrected.


Новое описание петиции:

As it became known from official sources, inIn Poland, which is a member of the European Union, one of the patients received poisoning while undergoing MRI treatment, where Dotarem was used. According to the description of the drug, it is an agent for contrast imaging in magnetic resonance imaging. The drug is in official circulation in the EU countries, as confirmed by the relevant documents.

The patient claims that he was adversely affected by the drug, causing toxic poisoning. The patient claims that according to the description, the gadolinium that was in the drug should be eliminated through the kidneys within one week. This did not happen. In addition, the patient alleges that 3.5 months after he underwent the MRI, he visited a treatment facility for tests and was found to have 3 times the amount of gadolinium in his system, with no excretion through the urine. The patient also claims that he developed systemic fibrosis throughout his body based on the use of Dotarem. This, in turn, has led to the patient's poor vision, his skin ceasing to be elastic and the first signs of physical exhaustion, which was not the case before he underwent an MRI scan with the drug in question. We consider it necessary to conduct a thorough examination so that competent persons can confirm or refute the fact that the use of the gadolinium-based drug is dangerous for human MRI scans.